Financial support for this study came from the National Institute on Drug Abuse (grants K24DA034621 and R01DA16065) and from the National Center for Research Resources (grant UL1RR025005), which is a component of the National Institutes of Health and the National Institutes of Health Roadmap for Medical Research.
Article first published online: 23 JUL 2012
Copyright © 2012 the American Association for the Study of Liver Diseases
Clinical Liver Disease
Special Issue: Hepatitis C Infection – Treatment in Special Populations
Volume 1, Issue 3, pages 69–72, July 2012
How to Cite
Sulkowski, M. S. (2012), Hepatitis C genotype 1 infection in HIV–Infected patients in the era of direct-acting antiviral therapy. Clinical Liver Disease, 1: 69–72. doi: 10.1002/cld.51
Potential conflict of interest: Mark S. Sulkowski received consulting fees and research grants (via Johns Hopkins University) from Abbott Laboratories, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Gilead, Janssen, Merck, Roche/Genentech, and Vertex.
- Issue published online: 23 JUL 2012
- Article first published online: 23 JUL 2012
- Manuscript Revised: 6 JUN 2012
- Manuscript Received: 30 MAY 2012